Fierce Drug Safety Week 2021 has ended
Back To Schedule
Wednesday, January 20 • 11:15am - 11:55am
Panel: Evaluate if your Organizations REMS Program Should be Outsourced or Developed Internally

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
avatar for Debbie Cheslow

Debbie Cheslow

Director, Risk Management Programs, PPD
Debbie Cheslow is a Director at PPD, a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Ms. Cheslow provides oversight for all REMS programs in the Peri and Post Approval Research Operations group... Read More →
avatar for Jason Ancell

Jason Ancell

Associate Director, Global Risk Management Strategy, REMS Development, Implementation & Operations, BMS
Jason Ancell is Associate Director, Global Risk Management for Bristol Myers Squibb (BMS).  In his current role, Jason provides risk management support for BMS’s immunomodulatory drug class, including U.S. REMS.  Jason has over twelve years’ U.S. REMS experience; ranging from... Read More →
avatar for Kishore Gopu

Kishore Gopu

Director, REMS Operations, Teva Pharmaceuticals
Kishore Gopu, M.S, MBA, is Director, REMS Operations and has been with Teva since 2007 and has served in many departments including Regulatory Affairs, Commercial Operations, Patient Solutions, Market Access, and Pharmacovigilance. Since joining Teva, Kishore has built REMS department... Read More →
avatar for Kal Elhoregy

Kal Elhoregy

Director REMS Programs, Amneal Pharmaceuticals
Kal Elhoregy is an accomplished healthcare industry executive with 23+ years’ experience focused on implementation of Risk Minimization Programs, Quality Management Systems and Pharmacovigilance Compliance for companies within the pharmaceutical industry.In his current role as a... Read More →

Wednesday January 20, 2021 11:15am - 11:55am EST